Logo

Nanogen Completes Acquisition of SynX

Apr 21, 2004

NEW YORK, April 21 (GenomeWeb News) - Nanogen of San Diego, Calif., today announced the closing of its all-stock acquisition of SynX Pharma of Toronto.

 

The company will issue approximately 1.6 million shares of its common stock to SynX shareholders at an exchange ratio of 0.123 Nanogen shares per each SynX common share. Additionally, Nanogen acquired CA $3.5 million ($2.6 million) of subordinated secured debentures of SynX in exchange for 300,000 shares of its common stock.

 

SynX is now a wholly owned subsidiary of Nanogen, nearly three months after the acquisition was first announced.

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.